Phase II Study of Ketoconazole Plus Granulocyte-Macrophage Colony-Stimulating Factor for Prostate Cancer: Effect of Extent of Disease on Outcome

Journal of Urology

Volumn 178, Issue 6, 2007, Pages 2372-2377

  Ryan, Charles J ^a   Weinberg, Vivian ^a   Rosenberg, Jonathan ^a   Fong, Lawrence ^a   Lin, Amy ^a   Kim, Jennifer ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

granulocyte macrophage colony stimulating factor; ketoconazole; neoplasm metastasis; prostate; prostatic neoplasms

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; DIETHYLSTILBESTROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; KETOCONAZOLE; PC SPES; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACCIDENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CLOTTING DISORDER; BONE PAIN; BRONCHOSPASM; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUODENUM PERFORATION; DYSGEUSIA; DYSPNEA; EVALUATION; FATIGUE; HEARING LOSS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPONATREMIA; MALE; MELANOMA; METASTASIS; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RASH; SECOND CANCER; SIDE EFFECT; SKIN BRUISING; SYNCOPE; THORAX PAIN; UREMIA; URINARY TRACT INFECTION; URINE RETENTION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYDROCORTISONE; INJECTIONS, SUBCUTANEOUS; KETOCONAZOLE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 35748983191     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.08.011     Document Type: Article

References (11)

1. Kassouf W., Tanguay S., and Aprikian A. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169 (2003) 1742
2. Dawson N.A., Conaway M., Halabi S., Winer E.P., Small E.J., Lake D., et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B study 9181. Cancer 88 (2000) 825
3. Oh W.K., Kantoff P.W., Weinberg V., Jones G., Rini B.I., Derynck M.K., et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 22 (2004) 3705
4. Harris K.W.V., Bok R.A., Kakefuda M., and Small E.J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 168 (2002) 542
5. Small E.J., Baron A., and Bok R. Simultaneous and antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80 (1997) 1755
6. Small E.J., Halabi S., Dawson N.A., Stadler W.M., Rini B.I., Picus J., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 (2004) 1025
7. Small E.J., Reese D.M., Um B., Whisenant S., Dixon S.C., and Figg W.D. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5 (1999) 1738
8. Rini B.I., Weinberg V., Bok R., and Small E.J. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21 (2003) 99
9. Bubley G.J., Carducci M., Dahut W., Dawson N., Daliani D., Eisenberger M., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol 17 (1999) 3461
10. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006) 3089
11. Simons J.W., Carducci M.A., Mikhak B., Lim M., Biedrzycki B., Borellini F., et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 12 (2006) 3394